CANVAS studies confirm heart benefits seen in EMPA-REG

SGLT2 inhibitors will become more popular with the combined CANVAS and CANVAS-RENAL studies showing the drugs decreased the risk of cardiovascular events in patients with type 2 diabetes. The landmark research, presented recently at the American Diabetes Association’s Scientific Sessions in San Diego, suggests the sodium-glucose cotransporter-2  (SGLT2) inhibitors will move up the line of ...

Already a member?

Login to keep reading.

© 2021 the limbic